Robin J Leatherbarrow
Overview
Explore the profile of Robin J Leatherbarrow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
1156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bell A, Yu Z, Hutton J, Wright M, Brannigan J, Paape D, et al.
J Med Chem
. 2020 Jun;
63(14):7740-7765.
PMID: 32575985
The leishmaniases, caused by species of protozoan parasites, are neglected tropical diseases with millions of cases worldwide. Current therapeutic approaches are limited by toxicity, resistance, and cost. -Myristoyltransferase (NMT), an...
2.
Mousnier A, Bell A, Swieboda D, Morales-Sanfrutos J, Perez-Dorado I, Brannigan J, et al.
Nat Chem
. 2018 May;
10(6):599-606.
PMID: 29760414
Rhinoviruses (RVs) are the pathogens most often responsible for the common cold, and are a frequent cause of exacerbations in asthma, chronic obstructive pulmonary disease and cystic fibrosis. Here we...
3.
Goncalves V, Brannigan J, Laporte A, Bell A, Roberts S, Wilkinson A, et al.
Medchemcomm
. 2017 Jun;
8(1):191-197.
PMID: 28626547
The parasite is the most widely distributed cause of recurring malaria. -Myristoyltransferase (NMT), an enzyme that catalyses the covalent attachment of myristate to the N-terminal glycine of substrate proteins, has...
4.
Yu Z, Brannigan J, Rangachari K, Heal W, Wilkinson A, Holder A, et al.
Medchemcomm
. 2016 Mar;
6(10):1767-1772.
PMID: 26962430
-Myristoyltransferase (NMT) represents an attractive drug target in parasitic infections such as malaria due to its genetic essentiality and amenability to inhibition by drug-like small molecules. Scaffold simplification from previously...
5.
Rackham M, Yu Z, Brannigan J, Heal W, Paape D, Barker K, et al.
Medchemcomm
. 2016 Mar;
6(10):1761-1766.
PMID: 26962429
-Myristoyltransferase (NMT) is a potential drug target in parasites. Scaffold-hopping from published inhibitors yielded the serendipitous discovery of a chemotype selective for NMT; development led to high affinity inhibitors with...
6.
Pitchford W, Kim H, Ivanov A, Kim H, Yu J, Leatherbarrow R, et al.
ACS Nano
. 2015 Jan;
9(2):1740-8.
PMID: 25635821
In the past two decades there has been a tremendous amount of research into the use of nanopores as single molecule sensors, which has been inspired by the Coulter counter...
7.
Paape D, Bell A, Heal W, Hutton J, Leatherbarrow R, Tate E, et al.
PLoS Negl Trop Dis
. 2014 Dec;
8(12):e3363.
PMID: 25522361
We have refined a medium-throughput assay to screen hit compounds for activity against N-myristoylation in intracellular amastigotes of Leishmania donovani. Using clinically-relevant stages of wild type parasites and an Alamar...
8.
Hutton J, Goncalves V, Brannigan J, Paape D, Wright M, Waugh T, et al.
J Med Chem
. 2014 Sep;
57(20):8664-70.
PMID: 25238611
Inhibitors of Leishmania N-myristoyltransferase (NMT), a potential target for the treatment of leishmaniasis, obtained from a high-throughput screen, were resynthesized to validate activity. Crystal structures bound to Leishmania major NMT...
9.
Olaleye T, Brannigan J, Roberts S, Leatherbarrow R, Wilkinson A, Tate E
Org Biomol Chem
. 2014 Sep;
12(41):8132-7.
PMID: 25230674
N-Myristoyltransferase (NMT) has been shown to be essential in Leishmania and subsequently validated as a drug target in Plasmodium. Herein, we discuss the use of antifungal NMT inhibitors as a...
10.
Brannigan J, Roberts S, Bell A, Hutton J, Hodgkinson M, Tate E, et al.
IUCrJ
. 2014 Jul;
1(Pt 4):250-60.
PMID: 25075346
The leishmaniases are a spectrum of global diseases of poverty associated with immune dysfunction and are the cause of high morbidity. Despite the long history of these diseases, no effective...